key: cord-0752295-uzzjfm2l authors: González, Claudia; García‐Huidobro, Francisco Gustavo; Lagos, Antonia Elisa; Aliaga, Rodrigo; Fuentes‐López, Eduardo; Díaz, Luis Antonio; García‐Salum, Tamara; Salinas, Erick; Toro, Adriana; Callejas, Claudio Andrés; Riquelme, Arnoldo; Medina, Rafael A.; Palmer, James N. title: Prospective assessment of smell and taste impairment in a South‐American coronavirus disease 2019 (COVID‐19) cohort: Association with the need for hospitalization and reversibility of dysfunction date: 2021-04-13 journal: Int Forum Allergy Rhinol DOI: 10.1002/alr.22798 sha: e2163bbe9e5f4519cbe24b6359c3054ff75629ed doc_id: 752295 cord_uid: uzzjfm2l nan Variable prevalence of smell and taste dysfunction caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection has been reported worldwide. 1,2 Although South American countries have been listed in the top ten of coronavirus disease 2019 (COVID-19) case numbers, 3,4 psychophysical data has not been reported in these regions. This study aimed primarily to determine the frequency of self-perceived taste impairment and smell measurement in COVID-19 patients, and secondly, to assess its association with the need for hospitalization. We report a prospective cohort study conducted during April-October 2020, approved by our Institutional Scientific Ethics Committee ( Figure S1 ). Cases were adults with a positive SARS-CoV-2 quantitative real-time polymerase chain reaction (qRT-PCR) and <15 days of ongoing symptoms. A chemosensory symptoms survey for self-reported olfactory and gustatory dysfunction (Table S1) , and the Spanish-American version of the 40-odorant University of Pennsylvania Smell Identification Test (UPSIT) (Sensonics International, Haddon Hts., NJ, USA) 5 were applied during the recruitment process (initial UPSIT [ i UPSIT]) and repeated 30 days after symptom onset (follow-up UPSIT [ f UPSIT]). Controls were individuals without SARS-CoV-2 infection with negative qRT-PCR, immunoglobulin M (IgM)-immunoglobulin G (IgG) for SARS-CoV-2, and asymptomatic 14 days after, paired by age and sex. An UPSIT was applied in this group, to compare olfactory dysfunction prevalence in healthy subjects against cases (Figure S2 ). Prospective cohort study analysis Statistical analysis included comparisons by t-test and chi-square for categorical variables. Univariate linear and logistic regression models were built to assess the associations between primary outcomes: i UPSIT score; Olfactory function improvement ( f UPSITi UPSIT); outpatient or hospitalized condition (dependent variable), and each of the independent variables of interest. Multivariate linear and logistic regression models were constructed with factors significantly associated with the univariate models' dependent variable. The Hosmer-Lemeshow test was used to assess the multivariate logistic regression models goodness-of-fit. A good model fit yields a p value >0.05. One hundred COVID-19 patients were enrolled (56 outpatients, 44 hospitalized). Five were lost during followup (one transferred to the intensive care unit [ICU] and four withdrew). Sixty-three controls were included. Demographics in both groups were similar (Table S2) . At enrollment, smell loss was self-identified in 73 of 100 (73%) cases and was perceived at 3.4 ± 1.9 (mean ± SD) days since symptom onset. At follow-up, 23 of 94 (24.4%) persisted with olfactory dysfunction. Dysgeusia was selfperceived in 51 of 100 (51%) at enrollment. Outpatients presented dysgeusia more frequently than hospitalized individuals ( i UPSIT was obtained at 9 ± 3.2 (mean ± SD) days. Outpatients were tested at 7.5 ± 3 versus 10.8 ± 2.6 (95% confidence interval [CI], 2.09-4.40; t = 5.584; p < 0.001) days in the hospitalized group. f UPSIT was administered on day 30.8 ± 2.2. Outpatients were tested at 30.7 ± 2 versus 31 ± 2.3 (95% CI, −0.66 to 1.15; t = 0.532; p = 0.59) days in the hospitalized group. i UPSIT scores were abnormal in 75 in 100 (75%) of COVID-19 patients, decreasing to 39 in 95 (41%) at f UPSIT (χ 2 = 23.12; p < 0.001). The i UPSIT score was 28.07 ± 7, improving to 32.8 ± 3.4 at f UPSIT (95% CI, 3.11-6.10; t = 6.128; p < 0.001). Olfactory dysfunction severity at enrollment and followup was: mild microsmia in 27 in 100 (27%) versus 21 in 95 (22.1%); χ 2 = 0.629; p = 0.42; moderate microsmia in 25 in 100 (25%) versus 15 in 95 (15.7%); χ 2 = 2.53; p = 0.11; severe microsmia in 11 in 100 (11%) versus 3 in 95 (3.1%); χ 2 = 4.496; p = 0.03; and anosmia in 12 in 100 (12%) versus 0 in 95 (0%); χ 2 = 12.15; p < 0.001 of subjects. Hospitalized patients were significantly older than outpatients (51.1 ± 14.6 vs. 34.6 ± 11.5 years, 95% CI, 11.6-22.3; t = 6.301; p < 0.001 Univariate and multivariate regression models (Table 2) showed that anosmia and odynophagia had a protective Odds Ratio (OR), while older age and a higher i UPSIT score were associated with a greater risk for hospitalization. We show a prevalent and partially reversible smell dysfunction, as reported elsewhere. 6 Age and better smell function were associated with a higher risk for hospitalization, whereas odynophagia decreased that risk. The inclusion of a matched control group validated our results, because control subjects had higher UPSIT scores, suggesting that the results observed in the COVID-19 cohort were not due to sociocultural reasons. Our findings are similar to two European studies, 7-9 which found that patients reporting smell loss were less 1.08 (1.02-1.14) 0.006 1.10 (1.02-1.19 likely to be admitted for COVID-19 than those with normosmia. Self-perceived dysgeusia may represent the loss of flavor perception secondary to smell dysfunction or a direct injury to taste buds. Age was associated with a lesser improvement in olfaction, as expected due to the decrease of olfactory neurons and a diminished renewal capacity of the olfactory epithelium with increasing age. 10 i UPSIT score was inversely associated with improvement in olfaction: patients with a higher i UPSIT score (better olfaction) have a smaller improvement after 1 month. The present study has the following limitations: (1) patients with smell impairment could have been more prone to participate; and (2) outpatients had greater smell loss and were tested with the UPSIT earlier than hospitalized patients. It is possible that due to a rapid recovery of smell function, the UPSIT scores were higher in hospitalized patients. SARS-CoV-2 induced disease produces a prevalent but highly reversible olfactory and taste dysfunction. Age and better olfactory function are associated with a greater risk for hospitalization, while odynophagia, as a symptom of COVID-19, appears to be a protective factor. We thank Richard L. Doty for his guidance and generosity. The authors have declared no conflicts of interest. Claudia González G. helped with the study design, recruited patients, collected and analyzed data, made figures and tables, interpreted data, and wrote the paper. Francisco Gustavo García-Huidobro, and Antonia Elisa Lagos recruited patients, collected clinical data, and wrote the paper. Erick Salinas, Adriana Toro, Rodrigo Aliaga, Luis Antonio Díaz, and Tamara García-Salum recruited patients, collected clinical data, and revised the paper. Eduardo Fuentes-López analyzed data, interpreted data, and wrote the paper. Claudio Andrés Callejas interpreted data and revised the paper. Arnoldo Riquelme helped with the study design, recruited patients, and revised the paper. Rafael A. Medina recruited patients, collected, analyzed, and interpreted data, provided funding for the study, and wrote the paper. James N. Palmer provided funding for the study, helped with the study design, analyzed and interpreted data, and wrote the paper. COVID-19: a systematic review and meta-analysis An interactive web-based dashboard to track COVID-19 in real time Development of the University of Pennsylvania smell identification test: a standardized microencapsulated test of olfactory function Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVID-19 patients Selfreported olfactory loss associates with outpatient clinical course in COVID-19 Prognostic factors in Spanish COVID-19 patients: a case series from Barcelona Smell and taste dysfunctions in COVID-19 are associated with younger age in ambulatory settings -a multicenter cross-sectional study Olfaction and aging: a minireview